A recent program aired on April 7, 2024, focused on the role of APOBECs, or apolipoprotein B mRNA-editing enzymes, in cancer treatment. These enzymes, which are part of the immune system, typically protect the body from viral infections. However, research led by Reuben S. Harris, PhD, chair of the UT Health San Antonio Department of Biochemistry and Structural Biology, reveals that in many cancer cases, APOBECs can become detrimental.
According to Dr. Harris, “APOBECs are DNA mutating enzymes that normally serve to protect us from invading viruses. But in many instances in cancer, they become dysregulated. Instead of destroying viruses, they end up damaging our genomes.” This duality presents a significant challenge in cancer treatment, where these once protective enzymes can turn into agents of harm.
APOBECs: From Protectors to Potential Villains
Dr. Harris emphasizes the alarming transformation of APOBECs in the context of cancer. He states, “In cancer, the good guys can become villains that do catastrophic damage.” With surgical resection being one of the standard treatments for tumors, the timing of intervention is crucial. Harris proposes that after the removal of an APOBEC-positive tumor, there is an opportunity to inhibit these enzymes to prevent further damage.
By stopping APOBECs from functioning post-surgery, researchers believe they can significantly reduce the risk of cancer recurrence or the development of resistance to medications. “If we can stop that, we can make all of these adverse events much less likely to happen,” Dr. Harris explains. This proactive approach could transform how clinicians manage cancer treatment and improve patient outcomes.
Implications for Future Cancer Therapy
The research conducted at the University of Texas Health Science Center in San Antonio highlights the potential for innovative cancer therapies focused on APOBECs. This collaboration aims to explore how scientific advancements can change medical practices across the globe, potentially leading to more effective strategies for combating cancer.
As researchers delve deeper into the mechanisms of APOBECs, the hope is to harness the power of these enzymes while mitigating their harmful effects. Dr. Harris expresses enthusiasm about the prospects of this research, stating, “That’s something we get really excited about every day.”
With ongoing studies and a focus on the dual nature of APOBECs, there is optimism in the scientific community regarding new therapeutic approaches that could ultimately improve the lives of cancer patients worldwide.
